The Role of Mutation Testing in Patients with Chronic Myeloid Leukemia in Chronic Phase after Imatinib Failure and Their Outcomes after Treatment Modification: Single-institutional Experience Over 13 Years

INTRODUCTION: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP). Over 100 BCR-ABL1 single-point mutations ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaitanya, Puligundla Krishna, Kumar, Karnam Ashok, Stalin, Bala, Sadashivudu, Gundeti, Srinivas, Maddali Lakshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686977/
https://www.ncbi.nlm.nih.gov/pubmed/29200684
http://dx.doi.org/10.4103/ijmpo.ijmpo_115_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686977/
https://www.ncbi.nlm.nih.gov/pubmed/29200684
http://dx.doi.org/10.4103/ijmpo.ijmpo_115_17

Ejemplares similares